MRVI Maravai Lifesciences Holdings Inc

Price (delayed)

$26.03

Market cap

$6.64B

P/E Ratio

13.42

Dividend/share

N/A

EPS

$1.94

Enterprise value

$6.62B

Maravai LifeSciences enables the development of drug therapies, diagnostics and novel vaccines and supports research on human diseases through its portfolio of market-leading companies and proprietary technologies. Maravai companies are ...

Highlights
The company's equity has surged by 135% YoY and by 19% QoQ
MRVI's net income has surged by 82% year-on-year and by 10% since the previous quarter
Maravai Lifesciences Holdings's quick ratio has surged by 114% YoY but it has decreased by 6% QoQ
Maravai Lifesciences Holdings's EPS has plunged by 76% YoY but it has increased by 5% from the previous quarter

Key stats

What are the main financial stats of MRVI
Market
Shares outstanding
255.21M
Market cap
$6.64B
Enterprise value
$6.62B
Valuations
Price to earnings (P/E)
13.42
Price to book (P/B)
14.55
Price to sales (P/S)
3.72
EV/EBIT
19.33
EV/EBITDA
17.42
EV/Sales
7.2
Earnings
Revenue
$920.28M
EBIT
$342.57M
EBITDA
$380.04M
Free cash flow
$479.13M
Per share
EPS
$1.94
Free cash flow per share
$3.64
Book value per share
$1.79
Revenue per share
$7
TBVPS
$12.61
Balance sheet
Total assets
$2.17B
Total liabilities
$1.4B
Debt
$529.1M
Equity
$456.59M
Working capital
$646.85M
Liquidity
Debt to equity
1.16
Current ratio
6.75
Quick ratio
5.96
Net debt/EBITDA
-0.06
Margins
EBITDA margin
41.3%
Gross margin
83.7%
Net margin
26.9%
Operating margin
70.4%
Efficiency
Return on assets
12.3%
Return on equity
68%
Return on invested capital
22.3%
Return on capital employed
16.6%
Return on sales
37.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

MRVI stock price

How has the Maravai Lifesciences Holdings stock price performed over time
Intraday
-2%
1 week
-1.33%
1 month
4.37%
1 year
-55.78%
YTD
-37.88%
QTD
-8.38%

Financial performance

How have Maravai Lifesciences Holdings's revenue and profit performed over time
Revenue
$920.28M
Gross profit
$770.07M
Operating income
$648.23M
Net income
$247.82M
Gross margin
83.7%
Net margin
26.9%
The operating income has surged by 102% year-on-year and by 3.1% since the previous quarter
MRVI's net income has surged by 82% year-on-year and by 10% since the previous quarter
Maravai Lifesciences Holdings's gross profit has surged by 75% YoY and by 3.4% QoQ
Maravai Lifesciences Holdings's revenue has soared by 67% YoY and by 2.8% from the previous quarter

Growth

What is Maravai Lifesciences Holdings's growth rate over time

Valuation

What is Maravai Lifesciences Holdings stock price valuation
P/E
13.42
P/B
14.55
P/S
3.72
EV/EBIT
19.33
EV/EBITDA
17.42
EV/Sales
7.2
Maravai Lifesciences Holdings's EPS has plunged by 76% YoY but it has increased by 5% from the previous quarter
The price to earnings (P/E) is 17% lower than the last 4 quarters average of 16.5
The company's equity has surged by 135% YoY and by 19% QoQ
MRVI's price to book (P/B) is 49% less than its last 4 quarters average of 28.9
Maravai Lifesciences Holdings's revenue has soared by 67% YoY and by 2.8% from the previous quarter
The price to sales (P/S) is 37% less than the last 4 quarters average of 6.0

Efficiency

How efficient is Maravai Lifesciences Holdings business performance
The return on equity has declined by 46% year-on-year and by 10% since the previous quarter
The company's return on invested capital rose by 14% YoY and by 5% QoQ
The return on assets has grown by 12% year-on-year
Maravai Lifesciences Holdings's ROS has increased by 7% YoY and by 5% from the previous quarter

Dividends

What is MRVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRVI.

Financial health

How did Maravai Lifesciences Holdings financials performed over time
MRVI's total assets is 55% greater than its total liabilities
Maravai Lifesciences Holdings's quick ratio has surged by 114% YoY but it has decreased by 6% QoQ
Maravai Lifesciences Holdings's current ratio has soared by 73% YoY but it has decreased by 5% from the previous quarter
The company's debt is 16% higher than its equity
The company's equity has surged by 135% YoY and by 19% QoQ
Maravai Lifesciences Holdings's debt to equity has shrunk by 62% YoY and by 17% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.